Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesChimeric Therapeutics Ltd

Chimeric Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.003 AUD 0.00(0%)
Last update at 2026-11-04T23:00:00Z
Market Cap
0.44M

Momentum Score

…

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Chimeric Therapeutics Ltd is an Australian clinical-stage biotechnology company developing engineered immune-cell therapies for oncology. Long-term growth drivers are clinical program progress, potential regulatory approvals, partnerships and scaling manufacturing for engineered cell therapies, which may appeal to investors seeking exposure to next-generation cancer immunotherapies.

Key risks include clinical or regulatory failure, substantial cash burn with the likely need for additional financing, and operational challenges such as complex manufacturing and strong competition in the cell-therapy sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
-0.19M
Revenue Per Share
-0.01
Gross Profit TTM
-0.19M
Debt / Equity
-0.09
ROE
-1290.99%
Net Debt
-0.12M
ROCE
109.80%
Diluted EPS TTM
-0.61

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -18.79M -10.32M -16.28M -25.41M -14.46M
Net income -18.81M -10.43M -12.53M -25.50M -14.62M
Selling general administrative - 7.05M 9.00M 14.88M 8.73M
Selling and marketing expenses - - 0.57M - -
Gross profit - 3.12M 7.45M - -
Reconciled depreciation - 1.03M 1.01M 0.97M 0.95M
Ebit - -10.11M -12.31M -24.98M -13.82M
Ebitda -8.36M -9.08M -11.30M -23.67M -12.87M
Depreciation and amortization - 1.03M 1.01M - 0.95M
Operating income -8.36M -15.11M -12.31M -25.41M -13.82M
Other operating expenses 8.36M 19.08M 19.77M - 17.19M
Interest expense - 0.21M 0.33M 0.85M 0.64M
Tax provision - 0.11M 0.01M 0.09M 0.16M
Interest income - 0.05M 0.12M 0.03M 0.01M
Net interest income - -0.16M -0.21M -0.75M -0.63M
Income tax expense 0.02M 0.11M -3.75M 0.09M 0.16M
Total revenue - 3.97M 7.46M 0.00M 0.00M
Total operating expenses 8.36M 18.23M 19.77M - 17.19M
Cost of revenue - 0.85M 0.00M - -
Total other income expense net -10.43M 4.79M -3.97M 4.83M 3.36M
Net income from continuing ops - -10.43M -12.53M -25.50M -14.62M
Net income applicable to common shares - -10.43M -12.53M -25.92M -15.90M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 1.28M 21.57M 15.27M 22.49M 34.88M
Intangible assets - 11.04M - 12.98M 13.65M
Other current assets 0.19M 0.22M 0.08M 0.33M 0.13M
Total liab 9.00M 19.60M 12.80M 16.41M 9.17M
Total stockholder equity -7.72M 1.97M 2.47M 6.08M 25.71M
Other current liab 2.81M 3.56M 6.90M 3.52M 4.32M
Common stock 80.41M - 63.51M 53.93M 51.81M
Capital stock - 70.16M - 53.93M 51.81M
Retained earnings -94.57M -76.33M -66.56M -56.78M -29.59M
Other liab - - - 2.02M 0.15M
Other assets - - - - 0.04M
Cash 0.80M 5.76M 3.05M 2.36M 18.38M
Cash and equivalents - - - - 18.38M
Total current liabilities 8.89M 14.61M 10.10M 14.69M 9.02M
Net debt -0.12M - -3.05M - -18.38M
Short term debt 0.68M - - - 0.00M
Short long term debt total 0.68M - - - -
Other stockholder equity - - - 8.51M -0.88M
Property plant equipment - - - 0.01M 0.02M
Total current assets 1.02M 10.53M 3.22M 9.35M 21.17M
Long term investments - - - 0.04M 0.04M
Net tangible assets - - - -7.32M 12.05M
Net receivables 0.03M - 0.09M 3.65M 3.54M
Long term debt - - - - 0.00M
Inventory - - - - -0.88M
Accounts payable 5.40M 6.57M 3.20M 7.41M 4.70M
Accumulated other comprehensive income 6.43M - 5.52M - 4.37M
Non currrent assets other - - 12.05M - -
Non current assets total 0.25M 11.04M 12.05M 13.02M 13.71M
Long term debt total - - - - 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M 0.00M -0.11M -0.04M
Change to liabilities - - - 4.74M 0.32M
Total cashflows from investing activities -0.25M - - -0.11M -0.58M
Net borrowings - - -2.28M -2.23M -4.05M
Total cash from financing activities 6.08M 10.05M 8.26M 0.25M 9.50M
Change to operating activities - - - 0.10M 0.10M
Net income -18.81M -10.43M -12.53M -25.92M -15.90M
Change in cash -4.96M 2.70M 0.69M -16.02M -4.03M
Begin period cash flow 5.76M 3.05M 2.36M 18.38M 22.41M
End period cash flow 0.80M 5.76M 3.05M 2.36M 18.38M
Total cash from operating activities -10.78M -7.28M -7.54M -16.31M -13.15M
Issuance of capital stock - 8.20M 11.74M 2.58M 14.90M
Depreciation - 1.03M 1.01M 0.97M 0.95M
Other cashflows from investing activities - - -7.55M 0.00M 0.01M
Change to account receivables - -0.01M 3.56M -0.99M -2.63M
Sale purchase of stock - -0.57M -1.20M 2.58M -1.31M
Other cashflows from financing activities -0.92M 2.41M -0.01M -0.10M -0.56M
Change to netincome - - - 4.80M 4.01M
Capital expenditures 10.78M 0.00M 7.55M 0.11M 0.54M
Change in working capital - -0.21M 1.60M 3.53M -0.00M
Stock based compensation - 1.09M 0.57M - -
Other non cash items 8.03M 1.25M 1.81M - -
Free cash flow - -7.28M 0.01M -16.42M -0.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CHM
Chimeric Therapeutics Ltd		 -
-%		 0.00 - - 0.07 4.95 2.60 -2.14
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Chimeric Therapeutics Ltd

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

62 Lygon Street, Carlton, VIC, Australia, 3053

61 3 9824 5254

https://www.chimerictherapeutics.com

Name Title Year Born
Ms. Jennifer Chow CEO, MD & Director NA
Mr. Eliot Bourk Chief Bus. Officer & Head of External Innovation NA
Dr. Li Ren VP of Technical Operations NA
Mr. Kelly R. Thornburg VP & Head of Quality 1963
Mr. Jason B. Litten M.D. Chief Medical Officer 1974
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA Sec. 1961
Mr. Nathan Jong C.A. Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Executive Chairman 1956
Mr. Eliot Bourk Chief Business Officer & Head of External Innovation NA
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO, Joint Company Secretary & Director 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…